The Kynurenine pathway: Modeling the interaction between genes and nutrition in Schizophrenia

Journal of Orthomolecular Medicine

Volumn 26, Issue 2, 2011, Pages 59-84

  Miller, Christine L ^a  

^a MillerBio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYANTHRANILIC ACID; 3 HYDROXYKYNURENINE; ADRENOCHROME; BUNGAROTOXIN RECEPTOR; CATECHOL METHYLTRANSFERASE; CERULOPLASMIN; CHLORPROMAZINE; COBALAMIN; COPPER; CYANOCOBALAMIN; DOPAMINE; DYSBINDIN; FLUPHENAZINE; FOLIC ACID; INDOLEAMINE 2,3 DIOXYGENASE; ISONIAZID; KYNURENIC ACID; KYNURENINE; METHIONINE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINIC ACID; OMEGA 3 FATTY ACID; PROMAZINE; PYRIDOXINE; THIORIDAZINE; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; UNINDEXED DRUG; XANTHURENIC ACID;

ANTIBACTERIAL ACTIVITY; DRUG EFFICACY; GENE INTERACTION; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; NONHUMAN; NUTRITIONAL HEALTH; NUTRITIONAL PARAMETERS; PROTEIN FUNCTION; PSYCHOSIS; PYRIDOXINE DEFICIENCY; REVIEW; SCHIZOPHRENIA; TRYPTOPHAN BRAIN LEVEL; TRYPTOPHAN METABOLISM; TUBERCULOSIS; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; WILSON DISEASE;

EID: 80054793724     PISSN: 03170209     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (240)

1. Hoffer A, Osmond H, Callbeck MJ, et al.: Treatment of schizophrenia with nicotinic acid and nicotinamide. J Clin Exp Psychopathol, 1957; 18: 131-158.
2. Hoffer A, Osmond H: The adrenochrome model and schizophrenia. J Nerv Ment Dis, 1959; 128(1): 18-35.
3. Schwarcz R, Rassoulpour A, Wu HQ, et al.: Increased cortical kynurenate content in schizophrenia. Biol Psychiatry, 2001; 50(7): 521-530. (Pubitemid 32971883)
4. Erhardt S, Schwieler L, Engberg G: Kynurenic acid and schizophrenia. Adv Exp Med Biol, 2003; 527: 155-165. (Pubitemid 38197640)
5. Nilsson LK, Linderholm KR, Engberg G, et al.: Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res, 2005; 80(2-3): 315-322. (Pubitemid 41713657)
6. Miller CL, Llenos IC, Dulay JR, et al.: Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex form individuals with schizophrenia and bipolar disorder. Brain Res, 2006; 1073-1074: 25-37.
7. Miller CL, Llenos IC, Cwik M, et al.: Alterations in Kynurenine Precursor and Product Levels in Schizophrenia and Bipolar Disorder. Neurochem Int, 2008; 52(6): 1297-1503.
8. Linderholm KR, Skogh E, Olsson SK, et al.: Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull, 2010; [PMID: 20729465; Epub ahead of print].
9. Sathyasaikumar KV, Stachowski EK, Wonodi I, et al.: Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull, 2010; [PMID: 21036897; Epub ahead of print].
10. Condray R, Dougherty GG, Keshavan MS, et al.: 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol, 2011; [PMID: 21275080; Epub ahead of print].
11. Hankes LV, Leklem JE, Brown RR, et al.: Tryptophan metabolism in patients with pellagra: the problem of vitamin B6 activity and feedback control of tryptophan pyrrolase enzyme. Am J Clin Nutr, 1971; 24 (6): 730-739.
12. Ackner B, Cooper JE, Gray CH, et al.: Acute porphyria: a neuropsychiatric and biochemical study. J Psychosom Res, 1962; 6: 1-24.
13. Wetterberg L: A Neuropsychiatric and Genetical Investigation of Acute Intermittent Porphyria. Stockholm, Sweden. Scandanavian University Books. 1967.
14. Morgan CJ, Badawy AA.:Effects of acute carbamazepine administration on haem metabolism in rat liver. Biochem Pharmacol, 1992; 43 (7): 1473-1477.
15. Heyes MP, Saito K, Lackner A, et al.: Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J, 1998; 12(10): 881-896. (Pubitemid 28294678)
16. Miller CL, Llenos IC, Dulay JR, et al.: Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiol Dis, 2004; 15(3): 618-629. (Pubitemid 38429977)
17. Bara H, Hainfellner JA, Kepplinger B, et al.: Kynurenic acid metabolism in the brain of HIV-1 infected patients. J Neural Transm, 2000, 107 (10): 1127-1138.
18. Bellac CL, Coimbra RS, Christen S, et al.: Pneumococcal meningitis causes accumulation of neurotoxic kynurenine metabolites in brain regions prone to injury. Neurobiol Dis, 2006; 24(2): 395-402 (Pubitemid 44572757)
19. Atlas A, Gisslen M, Nordin C, et al.: Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid. Brain Behav Immun, 2007; 21 (1): 86-91. (Pubitemid 44854444)
20. Holtze M, Asp L, Schwieler L, et al.: Induction of the kynurenine pathway by neurotropic influenza A virus infection. J Neurosci Res, 2008; 86(16): 3674-3683.
21. Green AR, Curzon G: Decrease of 5-hyroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature, 1968; 220: 1095-1097.
22. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes. A report of 14 cases and a review of the literature. J Affect Disord, 1983; 5(4): 319-332. (Pubitemid 14244152)
23. Frijters R, Fleuren W, Toonen EJ, et al.: Prednisolone-induced differential gene expression in mouse liver carrying wild type or a dimerizationdefective glucocorticoid receptor. BMC Genomics, 2010; 11: 359.
24. Sandmeier JJ, Celic I, Boeke JD, et al.: Telomeric and rDNA silencing in Saccharomyces cerevisiae are dependent on a nuclear NAD(+) salvage pathway. Genetics, 2002; 160: 877-889. (Pubitemid 34263455)
25. Avalos JL, Bever KM, Wolberger C: Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme. Mol Cell, 2005; 17: 855-868. (Pubitemid 40386946)
26. Lin SJ, Ford E, Haigis M, et al.: Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev, 2004; 18(1): 12-16. (Pubitemid 38090683)
27. Schmidt MT, Smith BC, Jackson MD, et al.: Coenzyme specificity of Sir2 protein deacetylases: implications for physiological regulation. J Biol Chem, 2004; 279(38): 40122-40129. (Pubitemid 39258287)
28. Domergue R, Castaño I, De Las Peñas A, et al.: Nicotinic acid limitation regulates silencing of Candida adhesins during UTI. Science, 2005; 308(5723): 866-870. (Pubitemid 40629269)
29. Murray MF. Nicotinamide: an oral antimicrobial agent with activity against both Mycobacterium tuberculosis and human immunodeficiency virus. Clin Infect Dis, 2003; 36(4): 453-460. (Pubitemid 36241311)
30. Bekierkunst A, Artman M. Tissue metabolism in infection. DPNase activity, DPN levels, and DPN-linked dehydrogenases in tissues from normal and tuberculous mice. Am Rev Respir Dis, 1962; 86: 832-838.
31. Windman I, Bekierkunst A. Oxidized and reduced forms of nicotinamide nucleotides in livers of tuberculous mice. Am Rev Respir Dis, 1967; 96(2): 296-298.
32. Kas?rov LB, Moat AG. Metabolism of nicotinamide adenine dinucleotide in human and bovine strainsof Mycobacterium tuberculosis. J Bacteriol, 1972; 110(2): 600-603.
33. Boshoff HI, Xu X, Tahlan K, et al.: Biosynthesis and recycling of nicotinamide cofactors in Mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. J Biol Chem, 2008: 11; 283(28): 19329-19341.
34. Cho-chung YS, Pitot HC: Feedback control of rat liver tryptophan pyrrolase. J Biol Chem, 1967; 242 (6): 1192-1198.
35. Cho-chung YS, Pitot HC: Regulatory effects of nicotinamide on tryptophan pyrrolase synthesis in rat liver in vivo. Eur J Biochem, 1968; 3 (4): 401-406.
36. Litdejohn TK, Takikawa O, Skylas D, et al.: Expression and purification of recombinant human indoleamine 2,3-dioxygenase. Protein Expr Purif, 2000; 19: 22-29. (Pubitemid 30387890)
37. Ren S, Liu H, Licad E, et al.: Expression of rat liver tryptophan 2,3-dioxygenase in Escherichia coli: structural and functional characterization of the purified enzyme. Arch Biochem Biophys, 1996; 333 (1): 96-102. (Pubitemid 26276978)
38. Schutz G, Feigelson P: Purification and properties of rat liver tryptophan oxygenase. J Biol Chem, 1972; 247 (17): 5327-5332.
39. Hayaishi O: Properties and function of indoleamine 2,3-dioxygenase. J Biochem, 1976; 79, 13-21.
40. Pfefferkorn ER, Rebhun S, Eckel M: Characterization of an indoleamine 2,3-dioxygenase induced by gamma-interferon in cultured human fibroblasts. J Interferon Res, 1986; 6: 267-279. (Pubitemid 16039051)
41. Ren S, Liu H, Licad E, et al.: Expression of rat liver tryptophan 2,3-dioxygenase in Escherichia coli: structural and functional characterization of the purified enzyme. Arch Biochem Biophys, 1996; 333 (1): 96-102. (Pubitemid 26276978)
42. Uchida K, Usami M, Bandow H, et al.: Characteristics of substrates and inhibitors in binding to rat liver L-tryptophan 2,3-dioxygenase: a Fourier transform infrared and kinetic study. Biochim Biophys Acta, 1992; 1121: 153-159.
43. Nagineni CN, Pardhasaradhi K, Martins MC, et al.: Mechanisms of interferon-induced inhibition of Toxoplasma gondii replication in human retinal pigment epithelial cells. Infect Immun, 1996; 64(10): 4188-4196. (Pubitemid 26318141)
44. Platten M, Ho PP, Youssef S, et al.: Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science, 2005; 310 (5749): 850-855. (Pubitemid 41567343)
45. Rao PV, Vaidyanahan CS: Enzymic conversion of 3-hydroxyanthranilic acid into cinnabarinic acid. Partial purification and properties of rat-liver cinnabarinate synthase. Biochem J, 1966; 99(2): 317-322.
46. Manthey MK, Pyne SG, Truscott JW: Mechanism of reaction of 3-hydroxyanthranilic acid with molecular oxygen. Biochim Biophys Acta, 1990; 1034: 207-212. (Pubitemid 20157829)
47. Gill M: Pigments of fungi (Macromycetes). Nat Prod Rep, 1999; 16: 301-317.
48. Eggert C, Temp U, Dean JF, et al.: Laccase-mediated formation of the phenoxazinone derivative, cinnabarinic acid. FEBS Lett, 1995; 376(3): 202-206.
49. Nappi AJ, Christensen BM: Melanogenesis and associated cytotoxic reactions: applications to insect innate immunity. Insect Biochem Mol Biol, 2005; 35(5): 443-459. (Pubitemid 40440937)
50. Phillips JP, Forrest HS, Kulkarni AD: Terminal synthesis of xanthommatin in Drosophila melanogaster. 3. Mutational pleiotropy and pigment granule association of phenoxazinone synthetase. Genetics, 1973; 73(1): 45-56.
51. Tomoda A, Yoneyama Y, Yamaguchi T, et al.: Spectroscopic studies of brunescent cataractous lenses. FEBS Lett, 1987; 219(2): 472-476.
52. Kanth VR, Lavanya K, Srinivas J, et al.: Elevated Expression of indoleamine 2,3-dioxygenase (IDO) and accumulation of kynurenic acid in the pathogenesis of STZ-induced diabetic cataract in Wistar rats. Curr Eye Res, 2009; 34(4): 274-281.
53. Mailankot M, Staniszewska MM, Butler H, et al.: Indoleamine 2,3-dioxygenase overexpression causes kynurenine-modification of proteins, fiber cell apoptosis and cataract formation in the mouse lens. Lab Invest, 2009; 89(5): 498-512.
54. Vogliardi S, Bertazzo A, Cornai S, et al.: An investigation on the role of 3-hydroxykynurenine in pigment formation by matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom, 2004; 18: 1413-1420. (Pubitemid 38868740)
55. Rózanowska M, Sarna T, Land EJ, et al.: Free radical scavenging properties of melanin interaction of eu- and pheo-melanin models with reducing and oxidising radicals. Free Radic Biol Med, 1999; 26(5-6): 518-525. (Pubitemid 29146254)
56. Kinnaert E, Morandini R, Simon S, et al.: The degree of pigmentation modulates the radiosensitivity of human melanoma cells. Radiat Res, 2000; 154(5): 497-502.
57. Dadachova E, Casadevall A: Ionizing radiation: how fungi cope, adapt, and exploit with the help of melanin. Curr Opin Microbiol, 2008; 11(6): 525-531.
58. Ings RM: The melanin binding of drugs and its implications. Drug Metab Rev, 1984; 15(5-6): 1183-1212.
59. Larsson BS. Interaction between chemicals and melanin. Pigment Cell Res, 1993; 6(3): 127-133.
60. Graham DG: Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol, 1978; 14(4): 633-643.
61. Offen D, Ziv I, Barzilai A, et al.: Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease. Neurochem Int, 1997; 31: 207-216. (Pubitemid 27267961)
62. Hoffer A: The adrenochrome theory of schizophrenia: a review. Dis Nerv Syst, 1964; 25: 173-178.
63. Smythies J: The adrenochrome hypothesis of schizophrenia revisited. Neurotox Res, 2002; 4(2): 147-150.
64. Kern C, Mautz DS, Bernards CM: Epinephrine is metabolized by the spinal meninges of monkeys and pigs. Anesthesiology, 1995; 83(5): 1078-1081.
65. Axelrod J: The metabolism storage and release of catecholamines. Recent Progr Hormone Res, 1965; 21: 597-622.
66. Guarnieri C, Ventura C: Inhibition by ceruloplasmin of the cardiac sarcolemmal adrenochrome formation. Biosci Rep, 1985; 5(6): 473-476. (Pubitemid 15047048)
67. Roberts A, Bar-Or D, Winkler JV, et al.: Copper-induced oxidation of epinephrine: protective effect of D-DAHK, a synthetic analogue of the high affinity copper binding site of human albumin. Biochem Biophys Res Commun, 2003; 304(4): 755-757. (Pubitemid 36513552)
68. Green S, Mazur A, Shorr E: Mechanism of the catalytic oxidation of adrenaline by ferritin. J Biol Chem, 1956; 220: 237-255.
69. Graham DG: Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol, 1978; 14(4): 633-643.
70. Galzigna L: Interaction of chloropromazine with adrenochrome and interference of a possible endogenous psychotogenic agent with some synaptic enzyme activities. Biochem Pharmacol, 1972; 21(2): 203-207.
71. LaBrosse EH, Axelrod J, Kpoin IJ, et al.: Metabolism of 7-H3-epinephrine-d-bitartrate in normal young men. J Clin Invest, 1961; 40: 253-260.
72. Perry TL: N-Methylmetanephrine: excretion by juvenile psychotics. Science, 1963; 139: 587-589.
73. Soddu G, Sanjust E, Murgia S, et al.: Interference of some tryptophan metabolites in the formation of melanin in vitro. Pigment Cell Res, 2004; 17: 135-141. (Pubitemid 38419640)
74. Chakraborty DP, Chowdhury SK, Dey RN, et al.: Interrelationship of tryptophan pyrrolase with tyrosinase in melanogenesis of Bufo melanostictus. Clin Chim Acta, 1978; 82(1-2): 55-59. (Pubitemid 8243082)
75. Rudin DO: The major psychoses and neuroses as omega-3 essential fatty acid deficiency syndrome: substrate pellagra. Biol Psychiatry, 1981; 16(9): 837-850.
76. Henderson LM, Gross CJ: Transport of niacin and niacinamide in perfused rat intestine. J Nutr, 1979; 109(4): 646-653. (Pubitemid 9158381)
77. Hara N, Yamada K, Shibata T, et al.: Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells. J Biol Chem, 2007; 282(34): 24574-24582. (Pubitemid 47347525)
78. Spector R: Niacin and niacinamide transport in the central nervous system. In vivo studies. J Neurochem, 1979; 33(4): 895-904.
79. Murray MF, Langan M, MacGregor RPv: Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. Nutrition, 2001; 17(7-8): 654-656. (Pubitemid 32633802)
80. Fukuwatari T, Shibata K: Effect of nicotinamide administration on the tryptophan-nicotinamide pathway in humans. Int J Vitam Nutr Res, 2007; 77(4): 255-262. (Pubitemid 350114346)
81. Hoffer A: Niacin Therapy in Psychiatry. Springfield, IL. C.C.Thomas, 1962.
82. 6 in mental functioning: a review of controlled trials in humans. Biol Psychiatry, 1991; 29(9): 931-941.
83. Revollo JR, Grimm AA, Imai S: The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem, 2004; 279(49): 50754-50763. (Pubitemid 40017813)
84. Wise A, Foord SM, Fraser NJ, et al.: Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem, 2003; 278(11): 9869-9874. (Pubitemid 36800490)
85. Gallo CM, Smith DL, Smith JS: Nicotinamide clearance by Pnc1 directly regulates Sir2-mediated silencing and longevity. Mol Cell Biol, 2004; 24(3): 1301-1312. (Pubitemid 38112191)
86. Behme MT: Nicotinamide and diabetes prevention. Nutr Rev, 1995; 53: 137-139.
87. Greenbaum CJ, Kahn SE, Palmer JP: Nicotinamide's effect on glucose metabolism in subjects at risk for IDDM. Diabetes, 1996; 45: 1631-1634. (Pubitemid 26357559)
88. Polo V, Saibene A, Portiroli AE : Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas. Acta Diabetol, 1998; 35: 61-64. (Pubitemid 28306257)
89. Goldberg RB, Jacobson TA: Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin Proc, 2008; 83(4): 470-478. (Pubitemid 351536472)
90. Benassi CA, Benassi P, Allegri G, et al.: Tryptophan metabolism in schizophrenic patients. J Neurochem, 1961; 7: 264-270.
91. Hrboticky N, Leiter LA, Anderson GH: Menstrual cycle effects on the metabolism of tryptophan loads. Am J Clin Nutr, 1989; 50(1): 46-52. (Pubitemid 19195519)
92. Gál EM, Young RB, Sherman AD: Tryptophan loading: consequent effects on the synthesis of kynurenine and 5-hydroxyindoles in rat brain. J Neurochem, 1978; 31(1): 237-244. (Pubitemid 8390999)
93. Gál EM, Sherman AD: L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res, 1980; 5(3): 223-239. (Pubitemid 10134133)
94. Gilka L: The Biochemistry of the Schizophrenias. Orthomol Psychiat, 1978; 7: 6-16.
95. Hoffer A: Mechanism of action of nicotinic acid and nicotinamide in the treatment of schizophrenia. In. eds. Hawkins D, Pauling L. Orthomolecular Psychiatry. San Francisco, CA, W.H. Freeman and Company. 1973; 202-262.
96. Ehrensvard G, Liljekvist J, Heath RG: Oxidation of 3-hydroxyanthranilic acid by human serum. Acta Chem Scand, 1960; 14(10): 2081-2088.
97. Domino EF, Krause RR: Free and bound serum tryptophan in drug-free normal controls and chronic schizophrenic patients. Biol Psychiatry, 1974; 8(3): 265-279.
98. Yao JK, Dougherty GG Jr, Reddy RD, et al.: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry, 2010; 15(9): 938-953.
99. Tortorella A, Monteleone P, Fabrazzo M, et al.: Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology, 2001; 44(4): 167-171. (Pubitemid 33036026)
100. Barry S, Clarke G, Scully P, et al.: Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol, 2009; 23(3): 287-294.
101. Badawy AA, Morgan CJ, Llewelyn MB, et al.: Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome. J Psychopharmacol, 2005; 19(4): 385-391. (Pubitemid 41003134)
102. Issa F, Gerhardt GA, Bartko JJ, et al.: A multi-dimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses. Psychiatry Res, 1994; 52(3): 237-249.
103. Lenard NR, Dunn AJ: Potential role for nonesterified fatty acids in beta-adrenoceptor-induced increases in brain tryptophan. Neurochem Int, 2005; 46(2): 179-187. (Pubitemid 41556625)
104. Lenard NR, Gettys TW, Dunn AJ: Activation of beta2- and beta3-adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther, 2003; 305(2): 653-659. (Pubitemid 36459183)
105. Lenard NR, Dunn AJ: Mechanisms and significance of the increased brain uptake of tryptophan. Neurochem Res, 2005; 30(12): 1543-1548. (Pubitemid 41813718)
106. Michael AF, Drummond KN, Doeden D, et al.: Tryptophan metabolism in man. J Clin Invest, 1964;43:1730-1746.
107. Silber BY, Schmitt JA: Effects of tryptophan loading on human cognition, mood, and sleep. Neurosci Biobehav Rev, 2010; 34(3): 387-407
108. Alexander F, Curtis GC, Sprince H, et al.: L-methionine and L-tryptophan feedings in non-psychotic and schizophrenic patients with and without tranylcypromine. J Nerv Ment Dis, 1963; 137:135-142.
109. Berlet HH, Matsumoto K, Pscheidt GR, et al.: Biochemical correlates of behavior in schizophrenic patients. Schizophrenic patients receiving tryptophan and methionine or methionine together with a monoamine oxidase inhibitor. Arch Gen Psychiatry, 1965; 13(6): 521-531.
110. Spaide J, Neveln L, Tolentino J, et al.: Methionine and tryptophan loading in schizophrenic patients receiving a MAO inhibitor: correlation of behavioral and biochemical changes. Biol Psychiatry, 1969; 1(3): 227-233.
111. Antun FT, Burnett GB, Cooper AJ, et al.: (1971) The effects of L-methionine (without MAOI) in schizophrenia. J. Psychiatr Res, 1971; 8: 63-71.
112. Miller CL, Murakami P, Ruczinski I, et al.: Two complex genotypes relevant to the kynurenine pathway and melanotropin function show association with schizophrenia and bipolar disorder. Schizophr Res, 2009; 113: 259-267.
113. Muntjewerff JW, Kahn RS, Blom HJ, et al.: Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry, 2006; 11(2): 143-149. (Pubitemid 43164615)
114. Smythies JR: The transmethylation and onecarbon cycle hypotheses of schizophrenia. Psychol Med, 1983; 13(4): 711-714.
115. Kalyanaraman B, Felix CC, Sealy RC: Semiquinone anion radicals of catechol(amine)s, catechol estrogens, and their metal ion complexes. Environ Health Perspect, 1985; 64: 185-198. (Pubitemid 16135789)
116. Kahn V: Effect of kojic acid on the oxidation of DL-DOPA, norepinephrine, and dopamine by mushroom tyrosinase. Pigment Cell Res, 1995; 8(5): 234-240.
117. Inchiosa MA: Enzymic oxidation of epinephrine with formation of an actomyosin adenosine triphosphatase inhibitor. Biochem Pharmacol, 1967; 16(2): 329-344.
118. Lovstad RA: Effect of NADH on the ceruloplasmin catalyzed oxidation of dopamine and noradrenaline. Acta Chem Scand, 1971; 25(8): 3144-3150.
119. Ryan TP, Miller DM, Aust SD: The role of metals in the enzymatic and nonenzymatic oxidation of epinephrine. J Biochem Toxicol, 1993; 8(1): 33-39.
120. Rosei MA, Foppoli C, Wang XT, et al.: Production of melanins by ceruloplasmin. Pigment Cell Res, 1998; 11(2): 98-102. (Pubitemid 128532956)
121. Greiner AC, Nicolson GA.: Pigment deposition in viscera associated with prolonged chlorpromazine therapy. Can Med Assoc J, 1964; 91(12): 627-635.
122. Van Woert MH: Proceedings: Phenothiazine drugs and melanin synthesis. Psychopharmacol Bull, 1974; 10(4): 41-42.
123. Monder C, Waisman HA: The nonenzymic conversion of dopa to melanin. IV. The inhibition of copper-catalyzed dopa oxidation by human blood plasma in leukemia and cancer. Cancer Res, 1959; 19(3 Part 1): 268-271.
124. Velez-Pardo C, Jimenez del Rio M, Ebinger G, et al.: Manganese and copper promote the binding of dopamine to "serotonin binding proteins" in bovine frontal cortex. Neurochem Int, 1995; 26(6): 615-622.
125. Remião F, Milhazes N, Borges F, et al.: Synthesis and analysis of aminochromes by HPLC-photodiode array. Adrenochrome evaluation in rat blood. Biomed Chromatog,. 2003; 17(1): 6-13.
126. Bollet AJ: Politics and pellagra: The epidemic of pellagra in the US in the early twentieth century. Yale J Biol Med, 1992; 65: 211-221.
127. Pennington JAT: Bowe's and Churche's Food Values of Portions Commonly Used. New York, NY. Harper Perennial, 1989.
128. Katz SH, Hediger ML, Valleroy LA: Traditional maize processing techniques in the newworld. Science, 1974; 184: 765-773.
129. Guillemin GJ, Cullen KM, Lim CK, et al.: Characterization of the kynurenine pathway in human neurons. J Neurosci, 2007; 27(47): 12884-12892. (Pubitemid 350161746)
130. Stead WW: Variation in vulnerability to tuberculosis in America today: random, or legacies of different ancestral epidemics? Intl J Tuberculosis Lung Dis, 2001; 5(9): 807-814.
131. van Crevel R, Ottenhoff TH, van der Meer JW: Innate immunity to Mycobacterium tuberculosis. Clin Microbiol Rev, 2002; 15(2): 294-309. (Pubitemid 34303767)
132. Fernando SL, Britton WJ: Genetic susceptibility to mycobacterial disease in humans. Immunol Cell Biol, 2006; 84(2): 125-137. (Pubitemid 43344666)
133. Konno K, Oizumi K, Shimizu Y, et al.: Niacin metabolism in mycobacteria. Mechanism of excess niacin production by human tubercle bacilli. Am Rev Respir Dis, 1966; 93(1): 41-46.
134. Young WD, Maslansky A, Lefar MS, et al.: Development of a paper strip test for detection of niacin produced by Mycobacteria. Appl Environ Microbiol, 1970; 20(6): 939-945.
135. Rangel Moreno J, Estrada García I, De La Luz García Hernández M, et al.: The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology, 2002; 106(2): 257-66.
136. Renz H, Gong JH, Schmidt A: Release of tumor necrosis factor-a from macrophages. Enhancement and suppression are dose-dependendy regulated by prostaglandin E2 and cyclic nucleotides. J Immunol, 1988; 141: 2388-2393.
137. Braun D, Longman RS, Albert ML: A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood, 2005; 106(7): 2375-2381. (Pubitemid 41510810)
138. Miller CL. The evolution of schizophrenia: a model for selection by infection, with a focus on NAD. Curr Pharm Des, 2009; 15(1): 100-109.
139. McMurray DN, Bartow RA: Immunosuppression and alteration of resistance to pulmonary tuberculosis in guinea pigs by protein undernutrition. J Nutr, 1992; 122(3) S: 738-743.
140. Mainali ES, McMurray DN: Protein deficiency induces alterations in the distribution of T-cell subsets in experimental pulmonary tuberculosis. Infect Immun, 1998; 66(3): 927-931. (Pubitemid 28101128)
141. 6 deficiency. Am J Clin Nutr, 1967; 20(6): 547-561.
142. 6 depletion. J Nutr, 1967; 93(1): 53-59.
143. Hollister LE, Moore FF, Forrest F, et al.: Antipyridoxine effect of D-penicillamine in schizophrenic men. Am J Clin Nutr, 1966; 19(5): 307-312.
144. Leklem JE, Brown RR, Rose DP, et al.: Metabolism of tryptophan and niacin in oral contraceptives users receiving controlled intakes of vitamin tit. Am J Clin Nutr, 1975; 28(2): 146-156.
145. 6 deficiency and tryptophan loading on urinary excretion of tryptophan metabolites in mammals. J Nutr, 1977; 107(2): 261-271.
146. Puri BK, Richardson AJ: Sustained remission of positive and negative symptoms of schizophrenia after treatment with eicosapentaenoic acid (letter). Arch Gen Psychiatry, 1998; 55: 188-189. (Pubitemid 28087605)
147. Fenton WS, Hibbeln J, Knable M: Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biol Psychiatry, 2000; 47: 8-21. (Pubitemid 30016075)
148. Horrobin DF: Omega-3 Fatty acid for schizophrenia. Am J Psychiatry, 2003; 160(1): 188-189.
149. Fenton WS, Dickerson F, Boronow J, et al.: A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry, 2001; 158(12): 2071-2074. (Pubitemid 33104119)
150. Calder PC: Polyunsaturated fatty acids and inflammation. Biochem Soc Trans, 2005; 33: 423-427.
151. Tang Y, Zhou L, Gunnet JW, et al.: Enhancement of arachidonic acid signaling pathway by nicotinic acid receptor HM74A. Biochem Biophys Res Commun, 2006; 345: 29-37.
152. Knowles HJ, te Poele RH, Workman P, et al.: Niacin induces PPAR gamma expression and transcriptional activation in macrophages viaHM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol, 2006; 71 646-656. (Pubitemid 43121998)
153. Wang M, Fotsch C: Small-molecule compounds that modulate lipolysis in adipose tissue: targeting strategies and molecular classes. Chem Biol, 2006; 13: 1019-1027. (Pubitemid 44557076)
154. Zhang Y, Schmidt RJ, Foxworthy P, et al.: Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A. Biochem Biophys Res Commun, 2005; 334: 729-732. (Pubitemid 40982427)
155. Richelsen B, Beck-Nielsen H: Decrease of prostaglandin E2 receptor binding is accompanied by reduced antilipolytic effects of prostaglandin E2 in isolated rat adipocytes, J Lipid Res, 1985; 26: 127-134. (Pubitemid 15133301)
156. Belenky P, Bogan KL, Brenner C: NAD+ metabolism in health and disease. Trends Biochem Sci, 2007; 32 12-19.
157. Filomeni G, Cardaci S, Da Costa Ferreira AM, et al.: Metabolic oxidative stress elicited by the copper(II) complex [Cu(isaepy)2] triggers apoptosis in SH-SY5Y cells through the induction of AMP-activated protein kinase/p38MAPK/p53 signalling axis Evidence for a combined use with 3-bromopyruvate in neuroblastoma treatment. Biochem J, 2011 [PMID: 21548882; Epub ahead of print]
158. Lönnerdal B: Bioavailability of copper. Am J Clin Nutr, 1996; 63(5): 821S-829S.
159. Fraga CG: Relevance, essentiality and toxicity of trace elements in human health. Mol Aspects Med, 2005; 26(4-5): 235-244.
160. Linder MC, Hazegh-Azam M: Copper biochemistry and molecular biology. Am J Clin Nutr, 1996; 63(5): 797S-811S. (Pubitemid 26126602)
161. Bowman MB, Lewis MS: The copper hypothesis of schizophrenia: a review. Neurosci Biobehav Rev, 1982; 6(3): 321-328. (Pubitemid 13254308)
162. Denning TR, Berrios GE: Wilson's disease: psychiatric symptoms of 195 cases. Arch Gen Psychiatry, 1989; 46: 1126-1134.
163. Huang CC, Chu NS: Wilsons disease: clinical analysis of 71 cases and comparison with previous Chinese series. J Formos Med Assoc, 1992; 91(5): 502-507.
164. Shanmugiah A, Sinha S, Taly AB, et al.: Psychiatric manifestations in Wilson's disease: a cross-sectional analysis. J Neuropsychiatry Clin Neurosc, 2008; 20(1): 81-85. (Pubitemid 351295032)
165. Akil M, Schwartz JA, Dutchak D, et al.: The psychiatric presentations of Wilson's disease. J Neuropsychiatry Clin Neurosci, 1991; 3: 377-382.
166. Jukić I, Titlić M, Tonkić A, et al.: Psychosis and Wilson's disease: a case report. Psychiatr Danub, 2006; 18(1-2): 105-107. (Pubitemid 44082090)
167. Lutsenko S, Efremov R, Tsivkovskii R, et al.: Human copper-transporting ATPase ATP7B (the Wilson's disease protein): biochemical properties and regulation. J Bioenerg Biomembr, 2002; 34: 351-362. (Pubitemid 36055729)
168. Steindl P, Ferenci P, Dienes HP, et al.: Wilsons disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology, 1997; 113(1): 212-218. (Pubitemid 27281776)
169. Harris ZL, Gitlin JD: Genetic and molecular basis for copper toxicity. Am J Clin Nutr, 1996; 63(5): 836S-841S.
170. Takahashi N, Ortel U, Putnam FW: Single-chain structure of human ceruloplasmin: the complete amino acid sequence of the whole molecule. Proc Natl Acad Sci USA, 1984; 81: 390-394. (Pubitemid 14185735)
171. Zaitsev VN, Zaitseva I, Papiz M, et al.: An X-ray crystallographic study of the binding sites of the azide inhibitor and organic substrates to ceruloplasmin, a multi-copper oxidase in the plasma. J Biol Inorg Chem, 1999 Oct; 4(5): 579-587. (Pubitemid 29500842)
172. Zgirski A, Frieden E: Binding of Cu(II) to nonprosthetic sites in ceruloplasmin and bovine serum albumin. J Inorg Biochem, 1990; 39(2): 137-148. (Pubitemid 20202650)
173. Hilton M, Spenser DC, Ross P, et al.: Characterisation of the copper uptake mechanism and isolation of the ceruloplasmin receptor/copper transporter in human placental vesicles. Biochim Biophys Acta, 1995; 1245(2): 153-160.
174. Martens S, Valbo S, Melander B: Studies on the role of ceruloplasmin in schizophrenia. Int Rev Neurobiol, 1959; 1333-342.
175. Feinstein RN: Cinnabarinate synthase activity in normal and acatalasemic mice. Proc Soc Exp Biol Med, 1978; 158(3): 398-401.
176. Cope-Yokoyama S, Finegold MJ, Sturniolo GC, et al.: Wilson disease: histopathological correlations with treatment on follow-up liver biopsies. World J Gastroenterol, 2010; 16(12): 1487-1494.
177. de Mol NJ: Interaction of phenothiazine drugs with human ceruloplasmin. Relation between activation of catecholamine neurotransmitter oxidation and electron donating ability of phenothiazine drugs. Biochem Pharmacol, 1985; 34(15): 2605-2609.
178. Seeman P: Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse, 1987; 1(2): 133-152.
179. 12. Vitam Horm, 2008; 79: 293-324.
180. Stead LM, Jacobs RL, Brosnan ME, et al.: Methylation demand and homocysteine metabolism. Adv Enzyme Regul, 2004; 44: 321-333. (Pubitemid
181. Rini J, Szumlanski C, Guerciolini R, et al.: Human liver nicotinamide N-methyltransferase: ion-pairing radiochemical assay, biochemical properties and individual variation. Clin Chim Acta, 1990; 186(3): 359-374. (Pubitemid 20040320)
182. Fuller RW, Marsh MM: Structure-activity correlation for substrates of phenylethanolamine N-methyltransferase (PNMT). J Med Chem, 1972; 15(10): 1068-1069.
183. 12) and folate deficiency. FASEB J, 1993; 7(14): 1344-53.
184. Regland B: Schizophrenia and single-carbon metabolism. Prog Neuropsychopharmacol Biol Psychiatry, 2005; 29(7): 1124-1132.
185. 12 levels and its implications for treating neuropsychiatric conditions: an orthomolecular perspective. J Orthomol Med, 2010; 25(2): 77-88.
186. 12 on neuropathy in pernicious anaemia treated with folic acid. Br Med J, 1950; 2(4671): 147-148.
187. 12 deficiency. Br Med J, 1967; 3(5556): 34.
188. 12 deficiency manifested as psychosis without anemia. Am J Psychiatry, 2000; 157(4): 660-661.
189. Chanarin I, Deacon R, Lumb M, et al.: Cobalamin-folate interrelations: a critical review. Blood, 1985; 66(3): 479-489. (Pubitemid 15230747)
190. 12 deficiency: a case for the methylfolate trap. Br J Haematol, 2006; 132(5): 623-629.
191. Greipp PR: Hyperpigmentation syndromes (diffuse hypermelanosis). Arch Intern Med, 1978; 138(3): 356-357.
192. 12 deficiency. Br Med J 1963; 1(5347): 1713-1715.
193. Marks VJ, Briggaman RA, Wheeler CE: Hyperpigmentation in megaloblastic anemia. J Am Acad Dermatol, 1985; 12(5 Pt 2): 914-917. (Pubitemid 15052575)
194. Sabatino D, Kosuri S, Remollino A, et al.: Cobalamin deficiency presenting with cutaneous hyperpigmentation: a report of two siblings. Pediatr Hematol Oncol, 1998; 15(5): 447-450. (Pubitemid 28450320)
195. 12 deficiency presenting with pancytopenia and hyperpigmentation. J Pediatr Hematol Oncol, 2004; 26(12): 834-836.
196. 12 deficiency-related neurological syndromes. Neurol India, 2005; 53(1): 55-58.
197. Kannan R, Ng MJ: Cutaneous lesions and vitamin B12 deficiency: an often-forgotten link. Can Fam Physician, 2008; 54(4): 529-532. (Pubitemid 351554051)
198. 12 deficiency in a young vegetarian woman. Acta Derm Venereol, 2008; 88(2): 191-192.
199. 12: need for clinical reevaluation and change. Vitamin B New Research. New York, NY. Nova Biomedical Books. 2008.
200. Haight RR, Norman RA: The cutaneous manifestations of vitamin deficiencies. Diagnosis of Aging, Skin Diseases; London, England. Springer Verlag Press, Inc. 2008.
201. 12. Proc Nutr Soc, 1999; 58(2): 441-448.
202. Antoniades C, Shirodaria C, Warrick N, et al.: 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation, 2006; 114(11): 1193-1201. (Pubitemid 44386484)
203. Nagatsua T: Biopterin cofactor and monoamine-synthesizing monooxygenases. Neurochem Int, 1983; 5(1): 27-38.
204. Spencer JD, Chavan B, Maries LK, et al.: A novel mechanism in control of human pigmentation by {beta}-melanocyte-stimulating hormone and 7-tetrahydrobiopterin. J Endocrinol, 2005; 187(2): 293-302. (Pubitemid 41685189)
205. Goldstein DS, Hahn SH, Holmes C, et al.: Monoaminergic effects of folinic acid, L-DOPA, and 5-hydroxytryptophan in dihydropteridine reductase deficiency. J Neurochem, 1995; 64(6): 2810-2813.
206. 12 in health and disease. Nutr Rev, 2004; 62(6 Pt 2): S3-12.
207. Miller CL, Dulay JR: The high affinity niacin receptor HM74A is decreased in the anterior cingulate cortex of individuals with schizophrenia. Brain Res Bull, 2008; 77(1): 33-41.
208. Lorenzen A, Stannek C, Lang H, et al.: Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol, 2001; 59 349-357. (Pubitemid 32108569)
209. Cheng K, Wu TJ, Wu KK, et al.: Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci, 2006; 103: 6682-6687.
210. Tunaru S, Kero J, Schaub A, et al.: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med, 2003; 9(3): 352-355. (Pubitemid 36362793)
211. Kirkland JB: Niacin status, NAD distribution and ADP-ribose metabolism. Curr Pharm Des, 2009; 15(1): 3-11.
212. Walters RW, Shukla AK, Kovacs JJ, et al.: beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. Clin Invest, 2009; 119(5): 1312-1321.
213. Saika Y, Kodama N, Kimura K, et al.: Plasma nicotinic acid levels in hemodialysis patients after the administration of niceritrol. Nippon Jinzo Gakkai Shi, 1999; 41(4): 430-435. (Pubitemid 29357365)
214. Baker H, Frank O, Pasher I, et al.: Nicotinic acid assay in blood and urine. Clin Chem, 1960; 6: 572-577.
215. Guilarte TR, Pravlik K: Radiometric-microbiologic assay of niacin using Kloeckera brevis: analysis of human blood and food. J Nutr, 1983; 113(12): 2587-2594. (Pubitemid 14222079)
216. Smythe GA, Poljak A, Bustamante S, et al.: ECNI GC-MS analysis of picolinic and quinolinic acids and their amides in human plasma, CSF, and brain tissue. Adv Exp Med Biol, 2003; 527: 705-712. (Pubitemid 38197703)
217. Nabokina SM, Kashyap ML, Said HM: Mechanism and regulation of human intestinal niacin uptake. Am J Physiol Cell Physiol, 2005; 289(1): C97-103.
218. Said HM, Nabokina SM, Balamurugan K, et al.: Mechanism of nicotinic acid transport in human liver cells: experiments with HepG2 cells and primary hepatocytes. Am J Physiol Cell Physiol, 2007; 293(6): C1773-1778. (Pubitemid 350255060)
219. Gobeil F, Fortier A, Zhu T, et al.: G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol, 2006; 84(3-4): 287-297. (Pubitemid 44481092)
220. Neuvonen PJ, Roivas L, Laine K, et al.: The bioavailability of sustained release nicotinic acid formulations. Br J Clin Pharmacol, 1991; 32(4): 473-476.
221. Menon RM, Adams MH, González MA, Tet al: Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation. Int J Clin Pharmacol Ther, 2007; 45(8): 448-454. (Pubitemid 47243941)
222. Taggart AK, Kero J, Gan X, et al.: (D)-beta-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J Biol Chem; 2005; 280(29): 26649-26652. (Pubitemid 41040696)
223. Shink, E., Harvey M., Tremblay,M., et al.: Analysis of microsatellite markers and single nucleotide polymorphisms in candidate genes for susceptibility to bipolar affective disorder in the chromosome 12Q24.31 region. Am J Med Genet B Neuropsychiatr Genet, 2005; 135: 50-58. (Pubitemid 40577855)
224. Severinsen JE, Als TD. Binderup H, et al.: Association analyses suggest GPR24 as a shared susceptibility gene for bipolar affective disorder and schizophrenia. Am J Med Genet B Neuropsychiatr Genet, 2006; 141: 524-533. (Pubitemid 44024447)
225. Baker BI, Ball JN: Evidence for a dual pituitary control of teleost melanophores. Gen Comp Endocrinol, 1975; 5: 147-152.
226. Allen N, Bagade S, McQueen MB, et al.: Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet, 2008; 40: 827-834. (Pubitemid 351913655)
227. Müller B, Kasper M, Surber C, et al.: Permeation, metabolism and site of action concentration of nicotinic acid derivatives in human skin. Correlation with topical pharmacological effect. Eur J Pharm Sci, 2003; 20: 181-195. (Pubitemid 37205211)
228. Li W, Zhang Q, Oiso N, et al.: Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet, 2003; 35: 84-89. (Pubitemid 37048600)
229. Freedman R. Olincy A. Ross RG, et al.: The genetics of sensory gating deficits in schizophrenia. Curr Psychiatry Rep, 2003; 5, 155-161. (Pubitemid 38899215)
230. Stassen HH, Bridler R, Hägele S, et al.: Schizophrenia and smoking: evidence for a common neurobiological basis? Am J Med Genet, 2000; 96: 173-177. (Pubitemid 30180858)
231. Leonard S, Gault J, Hopkins J, et al.: Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Arch Gen Psychiatry, 2002; 59: 1085-1096. (Pubitemid 35424018)
232. Stephens SH, Logel J, Barton A, et al.: 2009. Association of the 5′-upstream regulatory region of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophrenia Res, 2009; 109: 102-112.
233. Hilmas C, Pereira EFR, Alkondon M, et al.: The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci, 2001; 21: 7463-7473. (Pubitemid 32904945)
234. Adler LE, Hoffer LJ, Griffith J, et al.: Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry, 1992; 32(7): 607-616.
235. Shepard PD, Joy B, Clerkkin L, et al.: 2003. Micromolar brain levels of kynurenic acid are associated with disruption of auditory sensory gating in the rat. Neuropsychopharacology, 2003; 8: 1454-1462. (Pubitemid 41070880)
236. Ahmed CM, Johnson HM: IFN-gamma and its receptor subunit IFNGR1 are recruited to the IFN-gamma-activated sequence element at the promoter site of IFN-gammaactivated genes: evidence of transactivational activity in IFNGR1. J Immunol, 2006; 177(1): 315-321.
237. Alkelai A, Kohn Y, Olender T, et al.: Evidence for an interaction of schizophrenia susceptibility loci on chromosome 6q23.3 and 10q24.33-q26.13 in Arab Israeli families. Am J Med Genet B Neuropsychiatr Genet, 2009; 150B(7): 914-925.
238. Sugden K, Tichopad A, Khan N, et al.: Genes within the serotonergic system are differentially expressed in human brain. BMC Neurosci, 2009; 10: 50.
239. Hoffer LJ: Vitamin therapy in schizophrenia. Isr J Psychiatry Relat Sci, 2008; 45(1): 3-10.
240. Pataracchia RJ: Optimal dosing for schizophrenia. J Orthomol Med, 2005; 20(20): 93-99.